SUMMARY. Hyperammonaemia is associated with a high morbidity and mortality.
It is important to diagnose as it is often treatable and perhaps. most importantly. may be genetically determined.
Measurement of plasma ammonia is rarely necessary in adult medicine. In paediatrics, and particularly in the neonatal period, it is an important investigation in the diagnosis and often in the subsequent management of several inherited metabolic disorders. Patients with these disorders. particularly neonates. will deteriorate over a period of hours and investigation cannot wait. In these situations a plasma ammonia together with other investigations for metabolic disorders must be available urgently and arc sometimes necessary out of normal laboratory hours.
Interpretation must take into account the age and maturity of the child as well as the clinical state and results of other investigations. If treatment is initiated. frequent monitoring of plasma ammonia may be required.
Plasma ammonia can be reliably and conveniently measured using a specific ionselective electrode system or an automated enzyme method. Screening using a microdiffusion method is not a satisfactory alternative to a quantitative assay.
Plasma ammonia is no longer solely the province of the specialised paediatric laboratory. but should be part of the repertoire of every laboratory supporting neonatal or paediatric units. The threshold for accepting requests should be lower than at present if we are to prevent misdiagnoses.
Ammonia estimation remains a 'be/e noire of the Clinical Chemists' repertoire and. with the exception of specialist paediatric units. few laboratories have a quantitative method in routine use. This is largely because of historical difficulties in methodology and the instability of ammonium concentrations in body fluids which makes the collection and storage of specimens fraught with problems.
The clinical indications for measuring blood ammonia concentration arc fairly well defined and occur predominantly in sick neonates and children. The increasing clinical awareness of inherited metabolic disorders and the need to be able to diagnose hyperammonaemia, often urgently. means that blood ammonia investigations should be available in local laboratories. However. because of the analytical difficulties and hecause it is an infrequent request. it is often omitted from the laboratory repertoire with consequent 'under requesting'. This paper was prepared at the invitation of the Clinical Investigation Working Party of the Scientific Committee of the Association of Clinical Biochemists, but does not necessarily reflect their views. This paper briefly reviews the causes and clinical presentations of hyperammonaemia, and the analytical aspects of blood ammonia measurement and makes recommendations about when and how this analyte should be measured.
Ammonia metabolism
Ammonia is one of the major intermediates in the catabolism of nitrogen compoundsin man. To avoid difficulties in terminology (ammonia vs ammonium) 'ammonia' wi1l be used throughout this review to refer to the sum of ammonia gas and ammonium ion. Although. it is understood that at physiological pf-l, 99% is present as ammonium ions whereas measurement techniques may involve conversion to ammonia. Circulating ammonia is derived primarily from amino acids either from dietary protein or body protein ( Fig. I) with the gastrointestinal tract as the major production site. Despite constant production of ammonia. plasma ammonia is normally maintained at less than 40 umol/L. The liver is the most important organ in the maintenance of physiological ammonia concentrations in normal humans, although skeletal muscle assumes more importance in patients with advanced liver disease. The low plasma concentration is achieved by synthesis of glutamine from glutamate and ammonia and by urea synthesis in the liver ( Fig. 2) with approximately @-90% of waste nitrogen being excreted as urea. The condensation of ammonia and bicarbonate to carbamoyl phosphate requires N-acetyl glutamine as an activator. Carbamoyl phosphate enters the urea cycle by condensing with ornithine to yield citrulline which is exported from the mitochondria to the cytosol. Citrulline combines with aspartate to produce argininosuccinate which is then cleaved to yield arginine and fumarate. Finally, arginine is hydrolysed to regenerate ornithine and urea is produced. Ornithine is available for condensing with carbamoyl phosphate after transport into the mitochondrion. Failure of urea synthesis causes accumulation of ammonia and amino acids and depletion of arginine. Subnormal plasma urea concentrations may be seen in neonates with complete enzyme defects of the urea cycle, but in older patients with partial defects urea concentration is usually normal.
Orotic acid is an intermediary metabolite of pyrimidine synthesis and originates from carbamoyl phosphate. Urinary orotic acid is increased in several of the urea cycle defects as carbamoyl phosphate is diverted for pyrimidine synthesis as a means of removal of excess ammonia.
Causes of hyperammonaemia
Hyperammonaemia occurs in inborn errors of the urea cycle, and secondarily to some amino acid and organic acid disorders. Impaired liver function and occasionally other illnesses may produce significant hyperammonaemia. Causes are listed in Table I. INHERITED METABOI.IC DISORDERS Inherited metabolic disorders are summarised in Table 2 . These disorders arc rare, with a combined incidence for the urea cycle disorders in the order of I in 30 000. The most frequent urea cycle disorder is ornithine carbamoyl transferase (OCT) deficiency. followed by citrullinaemia and argininosuccinic aciduria. For further information the reader is referred to more detailed reviews.': 2
OTHER CAUSES OF IIYPERAMMONAEMIA IN TIl E N EON ATE
Transient hyperammonaemia ill the newborn Transient hyperammonaemia of unknown cause:' can present as an overwhelming lifethreatening illness in the first 48 h of life. It is important to recognised this condition promptly as the outcome is good if treated early and aggressively (see below). Data on 15 survivors have shown a normal outcome in II cases at ages 2 months to 3 ycars. This condition is more likely to occur in pre-term infants (of less than 36 weeks' gestation) and usually presents with respiratory distress within 24 h of birth. oJ Plasma ammonia is very high, usually higher than 1500 umol/L, and plasma glutamine may be increased. Urinary orotic acid was normal in those patients tested. Presentation may be indistinguishable from amino acid, organic acid or urea cycle disorders and. therefore. inherited metabolic disorders must be excluded before a diagnosis of transient hyperammonaemia can be made. The pathogenesis of this condition is not known. although it may be triggered by tissue hypoxia or caused by poor perfusion through the liver.
Intravenous feeding
Hyperammonaemia has been reported as a complication of total parenteral nutrition (TPN).5 In one study" 45 patients receiving TPN had their blood ammonia measured and of these, 73'Yo had elevated values on one or more occasions. Higher concentrations occurred in the low-birth-weight infants. and in four infants blood ammonia concentrations of 140-345 umol/L were associated with lethargy or coma.
Glutamate Acetyl CoA
CoA-4----/ (6) HCOv Sick pre-term neonates may have mild to moderate elevation of plasma ammonia of up to 200 umol/L (venous blood or aterial catheter)" and in the absence of significant clinical or other biochemical findings suggesting a metabolic disorder. such infants do not require further investigation. Goldberg') studied 12 infants with severe perinatal asphyxia and found they had significant hyperammonaemia (215-684 umol/L) in the first 24 h of life. All patients had eNS dysfunction and five died. The contribution of the hyperammonaemia to the clinical outcome in these infants is not known.
Infection should always be considered as a cause of mild to moderate hyperammonaemia in the neonate and appropriately investigated. Disseminated herpes simplex has also been implicated. III
OTHER CAUSES OF HYPERAMMONAEMIA IN

INFANT/CHI LO/ ADU LT
Sodium valproate therapy
A small number of patients taking sodium valproate have become lethargic or comatosed with an associated increased plasma ammonia (greater than 60 umol/L) without signs of hepatic dysfunction. I I When valproate was discontinued, the level of consciousness improved,
In other children there is liver dysfunction and a 'Reye-like' syndrome may develop.P Hjelm has suggested that individuals at risk from valproate toxicity may have an underlying . inherited urea cycle defect':' and has recommended that urea cycle defects be excluded before valproate treatment is started.':' Certainly any patient on valproate with disturbed consciousness and/or evidence of liver dysfunction should have blood ammonia measured and be investigated for a metabolic disorder.
Reye's syndrome In 1963 Reye described a syndrome of acute encephalopathy and fatty degeneration of the liver. The illness usually starts with profuse and persistent vomiting. which is associated with or rapidly followed by a change in the child's mental state. In many cases the syndrome is preceded by a viral illness and recently salicylate has been implicated in the aetiology. 15 The syndrome is associated with characteristic tissue histology consistent with mitochondrial damage. The pathogenesis of Reye's syndrome is multifactorial and it seems likely that the clinical manifestation is a result of overwhelming mitochondrial injury from a variety of causes. Many infants/children presenting with a 'Reye-like' syndrome have an underlying disorder of the urea cycle, organic acid or fatty acid metabolism. The clinical syndrome is accompanied by characteristic biochemical changes which include markedly increased aminotransferase activity. prolonged prothrombin time. hypcrammonaemia and sometimes hypoglycaemia. These abnormalities may be useful clues, but are not diagnostic and they should trigger further investigations for metabolic disorders. Any patient suspected of having Rcye's syndrome regardless of age should be fully investigated for an underlying metabolic disorder especially if the episode is recurrent or occurs in more than one family member.
Liver disease
Ammonia presented to the liver cell for detoxification arises principally in the gastrointestinal tract by bacterial degradation of dietary protein or blood. Increased plasma ammonia may occur in both acute onset hepatic failure or advanced chronic liver disease. It is a non-specific finding and is of no value in either the differential or assessment of the degree of dysfunction in hepatobiliary disease:
Plasma and CSF ammonia is increased in most patients with hepatic coma although there is poor correlation with the degree of encephalopathy.!" It is only useful to measure plasma ammonia in such a situation if evidence of hepatocellular dysfunction as a contributor to encephalopathy is being sought. There is no value in measuring plasma ammonia for either early diagnosis or monitoring response to treatment.
It should be remembered that the clinical presentation of inherited metabolic disorders of the urea cycle in the older child or adult may resemble hepatic encephalopathy. with the exception that jaundice i~rare in inborn errors of metabolism. Therefore. these disorders should always be considered in hyperammonaemia of unknown cause. particularly if primary liver disease is not clinically evident.
Urinary tract infection
Hyperammonaemia due to bacterial infection has been reported in patients with urinary tract distension and stasis'?: III and should be considered in unexplained encephalopathy without liver disease.
Leukaemia
Transient hyperammonaemia without evidence of liver dysfunction has been reported in three adults undergoing treatment for acute leukaemia.!" In two cases the outcome was fatal. A further patient with chronic myelomonocytic leukaemia and unexplained coma had hyperammonaemiar"
These cases again highlight the importance of early recognition of hyperammonaemia as a possible cause of unexplained coma and the need to initiate agressive treatment (see below).
General illness
Infants/children in a collapsed/moribund state may have moderately elevated plasma ammonia (up to 300 Ilmo1lL)21 and a high level in such a situation does not suggest an inherited metabolic disorder.
Clinical presentation
The symptoms of hyperammonaemia are similar whatever the cause. and are related to age. time course and severity of the rise in plasma ammonia. Acute hyperammonaemia results in a syndrome of lethargy. vomiting and seizures which can lead to coma and death. Chronic recurrent hyperammonaemia is associated with irreversible brain damage and mental retardation.
In the neonate with an inborn error of metabolism onset is usually within the first
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week of life and often as early as the first day. Early symptoms include lethargy. refusal to feed. vomiting. irritability. seizures and tachypnoea. Ammonia is a respiratory stimulant and the presence of a respiratory alkalosis is an important clue to diagnosis. A very low blood urea (less than 1 mmollL) may occur. A family history of male neonatal deaths should raise suspicion of ornithine carbamoyl transferase deficiency. Neonates with a urea cycle defect may develop liver failure and pulmonary or intra-cranial haemorrhage can occur.
In infancy and childhood the presentation is more variable. Symptoms include feeding difficulties and vomiting. irritability and failure to thrive. There may be associated neurological signs and delayed development.
In children and adults presentation may be episodic with hyperammonaemia ranging from mild to severe. Mild hyperammonaemia is associated with irritability and headaches and progresses to lethargy. confusion and slurred speech. In severe hyperammonaemia there are usually neurological signs and disturbed consciousness.
In a susceptible individual hyperammonaemia may be precipitated by increased protein intake (including a gastrointestinal bleed). constipation. intercurrent infection or some other stress.
The first attack can occur quite late in childhood or even in an adult. and the occurrence of such an episode in a previously well child should not be dismissed as needing no further investigation. Hyperammonaemia should be considered in any child thought to have 'encephalitis' or undiagnosed encephalopathy.
Indications for measurement of plasma ammonia
Measurement of plasma ammonia is an important test in paediatrics and hy:r.;rammonaemia is commonly underdiagnosed. The main clinical situations where measurement is indicated are:
(1) Any neonate with unexplained neurological deterioration. Useful clues, are a respiratory alkalosis and an inappropriately low plasma urea. A history of male deaths in the family is strongly suggestive of ocr deficiency.
(2) A child or adult with an unexplained episodic illness (lethargy. vomiting), particularly if precipitated by protein intake.
(3) A child or adult with unexplained encephalopathy or 'encephalitis'.
Plasma ammonia estimation is only part of the investigation for inherited metabolic disorders and interpretation can only be made with the knowledge of results of other biochemical investigations. It is important to investigate unexplained hyperammonaemia to establish the underlying cause.
Treatment of hyperammonaemia
Hyperammonaemia is not a diagnosis and further investigations will be required urgently to establish the cause. In the meantime. because of the risk of long-term neurological damage severe hyperammonaemia (greater than 300 umol/L) should be treated promptly to minimise permanent handicap.
Infants subjected to prolonged hyperammonaemia coma (more than 5 days) have a very poor outcome associated with severe handicap.F Life-threatening episodes should be treated by protein withdrawal with adequate provision of calories from other substrates. Aggressive therapy with dialysis may be required. haemodialysis being preferred to peritoneal dialysis if expertise is available. 2Ẽ xchange transfusion has little to offer in this situation.
Persistent hyperammonaemia requires longterm treatment by dietary protein restriction and other measures. e.g. special diet. depending on the cause. In the urea cycle disorders. arginine becomes an essential amino acid and supplements are necessary to promote normal growth.
Another approach to treatment is to promote excretion of nitrogenous compounds by supplying sodium benzoate or sodium phenylacetate. 2 4-27 Before these specific dietary treatments are started, however, it is essential that secondary causes of hyperammonaemia (i.e. organic acid disorders or Reye's syndrome associated with salicylate ingestion) are excluded, as these measures, particularly benzoate, may be contra-indicated. The safety of benzoate in the jaundiced neonate remains uncertain as theoretically it will displace bilirubin from albumin and may cause kernicterus. Treatment of the urea cycle disorders requires regular monitoring of plasma ammonia and relevant amino acids. In the early stages of treatment in an acute situation, measurement may be required daily, or even two or three times a day if dialysis is in use. In the longer term. frequency of measurement will depend on the stability of the patient and occurrence of intercurrent infections and other stresses. If sodium benzoate is used it is desirable to monitor plasma benzoate/" and plasma sodium concentrations.
Further investigation of hyperammonaemia
Other biochemical tests which should be performed if hyperammonaemia is present are: tests for liver dysfunction; plasma (quantitative) and urine (qualitative) amino acids; urine organic acids; urine orotic acid.
These additional investigations are particularly important if the child is labelled as having Reye's syndrome. In an emergency appropriate specimens (urine. plasma. skin. liver) should be collected and stored for further investigations by a specialist laboratory.P'
In the acutely ill neonate the differential diagnosis as to whether hyperammonaemia is due to an urea cycle defect or to an organic acidaemia is very important as the treatment differs. Metabolic acidosis. ketonuria and neutropenia point to an organic acid disorder; respiratory alkalosis and an inappropriately low plasma urea are more likely to be due to a urea cycle defect.
In the neonatal forms of OCT and CPS deficiency the plasma ammonia level is usually grossly elevated (in excess of 500 umol/L). In the other urea cycle disorders the degree of hyperammonaemia is variable and depends on severity of the defect and protein intake. Patients with the milder clinical presentations may have an only minimally increased concentration and when fasted. plasma ammonia may be normal. In patients with mild or episodic symptoms it is. therefore. important to measure plasma ammonia. amino acids and urinary orotic acid after a protein meal.
Citrullinaemia, argininosuccinic aciduria and argininaemia can be diagnosed by blood and urine amino acid investigations. Although OCT and CPS deficiency may be associated with increased glutamine and alanine these amino acid abnormalities are not diagnostic and enzyme measurements in fresh liver are required. Alternatively, specific DNA probes for the diagnosis of OCT deficiency are available.
A guide to the differential diagnosis of inborn errors of metabolism presenting with hyperammonaemia in the neonate is outline in Fig. 3 . For further information the reader is referred to more detailed reviews. I 
3.~
Ammonia measurement
Accurate and precise measurement of plasma ammonia is difficult because of potential contamination either from exogenous sources or from the endogenous production of ammonia during transport and storage of the specimen. Reluctance to perform an ammonia estimation often arises because of these difficulties rather than because the request is inappropriate.
SPECIMEN COLLECTION/TRANSPORT/ STORAGE
For accurate ammonia measurement meticulous attention must be paid both to the quality of specimen and transport/storage conditions. Venous plasma anticoagulated with sodium or lithium heparin is recommended: beware of tubes which use ammonium heparin as anticoagulant. Batches of tubes should be checked for contamination. This can be done by adding the lowest working standard to a selection of five tubes taken at random from the batch. Mix well and analyse. If the maximum increase is less than 10% of the standard, the batch can be accepted. Tubes should be stored in an airtight container. Ammonia-free water is prepared by treating the laboratory supply of deionised/ distilled water with a suitable resin (e.g, Dowex-50W) or alternatively using a commercial deioniser e.g. Water-I (Gelman Sciences Ltd, Brackmills, Northampton. UK). Capillary blood can be used, but the skin must be thoroughly cleansed (e.g. Steret swab containing 70% isopropyl alcohol) to avoid contamination with sweat." Ammonia values are generally higher in capillary than venous specimens" and the difference is greater in neonates." This difference is possibly due to release of ammonia because of platelet activation in the fingerprick wound?" accentuated in the neonate by a combination of poor peripheral ctrculationP and organ immaturity. Although in neonates capillary blood produces significantly higher results than venous blood. it is unlikely to cause misdiagnosis of clinically significantly hyperammonaemia and where venous blood taking is compromised. capillary plasma can be a useful 'screen'. High concentrations must, however, be confirmed on venous blood. Capillary specimens are unsuitable for the accurate measurements that are required for monitoring treatment. Erythrocyte ammonia is higher than plasma ammonia" so that visibly haemolysed samples are unsuitable. Plasma should be separated from erythrocytes (is quickly as possible and centrifuged with sufficient force to sediment platelets (Z()(K) g). Whole blood should not be stored. even on ice (+4°C). as significantly higher ammonia concentrations arc found after I h. 34 Storage of plasma also leads to increased ammonia levels via deamination of amino acids. and plasma stored at +4°C or even -zlfe shows considerable variability in ammonia concentrations."
In summary. non-haemolysed heparinised (ammonia-free) venous plasma which has been separated from erythrocytes with sufficient force (2(K)() g) is recommended. It is not necessary to transport from the ward to laboratory on ice. but the specimen should be centrifuged at + 4°C. within 15 min of collection. Ideally plasma should be assayed at once. but if storage is unavoidable it should be at -70"C.
METIIOJ)OLOGY
Assay for ammonia should take place in an atmosphere free from contamination (e.g. ammonia-containing chromatography solvents). Care must be taken to avoid exogenous sources of ammonia from glassware." or equipment. e.g. analyser tubing. as a possible source of urease:'?
Plasma ammonia can be determined by a variety of methods. most of which include some form of separation process before analysis. First. ammonium is separated from its matrix either by adsorption on to a resin or by conversion to ammonia using alkali followed by gaseous diffusion. Ammonia can then be quantitated colorimetrically or by a specific electrode. Alternatively. enzymatic methods are available.
MICROJ)IFI'USION METHOJ)
These methods arc at best only semiquantitative. with poor precision. A microdiffusion method is commercially available as a Blood Ammonia Test Kit (Clandon Scientific Instruments Ltd. Aldershot, Hampshire. UK) (previously called 'Swiftest') which in the author's experience can be a useful screening method for gross hyperammonaemia. The kit is based on a microdiffusion methcd'" in which ammonia is liberated from whole blood by alkali and then diffuses across a polypropylene film where it reacts with bromocresol green. The colour produced is then compared to a standard test strip to give a semiquantitative result. Sample volume is only 2() ul, of whole blood and a result is available within 15 min. In the author's experience a concentration below 35 I1moVL using this screening method can be . regarded as normal. A grossly increased concentration (greater than 30() I1moVL) should be followed up urgently by a quantiative procedure and other appropriate investigations. All results higher than 35 I1moVL, however, must be followed up with a reliable quantitative assay as falsely high results can occur. Reflectance meters (Blood Ammonia Checker, Kyoto Daiichi Kagaku Co Ltd, Kyoto, Japan) have been used to obtain a quantitative result and claimed by some to compare well to enzymatic and ion-exchange methods;": 40 this favourable experience is not shared by others" including the author as the meter is difficultto standardise and can givegrosslyerroneous results. Although this method has the advantage of speed, simplicity and small sample volume it should not be used as a quantitative procedure. If used as a screening procedure, it should be restricted to the visual mode.
RESIN METHOD
Reliable methods are available using separation with an ion-exchange resin followed by colorimetry. Micro-methods have been devised'": 42 with between-batch precision of % at an ammonia concentration of J()() I1moVL. Their major disadvantage is that they are time-consuming, tedious and unsuitable for emergency use.
More recently a dry film method using the Ektachem (Eastman Kodak, Hemel Hempstead, Herts, UK) has become available. Evaluation has shown satisfactory precision and good correlation with an ion-exchange method.Y
ION SELECTIVE ELECTRODE
In 1973 Park and Fenton'" described the application of a specific electrode system for measurement of ammonia in plasma. This method is both simple and reliable when used in the continuous flow mode and at concentrations around 100I1moVL has a within-batch precision of less than 2%. The limit of detection of this method is 30 umol/l, which is higher than resin methods, but this is not a problem in practice. If continuous flow equipment is not otherwise available (i.e. proportioning pump, recorder) the initial outlay on equipment can be considerable (approximately £1500 in 1986), but running costs are negligible.
Both the author and colleagues'S' 46 have
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found the method to be robust and reliable even if used infrequently. Results can be obtained within 10-15 min of blood taking. Between-batch precision is acceptable with coefficient of variation of approximately 5-8% at 100-200 umol/L. One possible disadvantage is the larger sample volume (approximately 500 ul, plasma) than that required for enzymatic methods.
ENZYMATIC METHODS
Enzymatic methods are available in kit form and involve the formation of glutamate from alpha-keto glutarate catalysed by glutamate dehydrogenase. The conversion of NADH (or. NADPH) to NAD+(NADP+) is then measured spectrophotometrically or f1uorimetrically. The author's experience of these kits when used manually and infrequently by different operators is poor, as they are prone to interference and consequent imprecision. Such methods can be modified for use with centrifugal analysers." These methods have the advantages of small sample volume (approximately 20 uml, plasma), speed and suitability for emergency use. Between-batch precision of 4-7% at 100-300 umol/L can be achieved.r?: <Ill Choice of method depends on availability of equipment, technical expertise and frequency of requests. The ion-selective electrode system satisfies the essential requirements of speed, reliability and simplicity; because of the high capital outlay it is probably best suited to those laboratories where there is a significant workload.
Experience of cornmerical enzyme kits used routinely on automated analysers (e.g. centrifugal analyser) is favourable'" and if suitable equipment is available these kits may be more appropriate for laboratories with very few requests.
Whatever method is used, the most important aspect of plasma ammonia measurement is quality of specimen collection and control of exogeneous contamination. With strict attention to such detail, reliable results can be obtained on small samples of blood..
QUALITY ASSURANCE
Quality assurance is difficult because of the inherent instability of ammonia in plasma or whole blood specimens. In practice an aqueous ammonium solution with added stabiliser.(Preciset Ammonia; Boehringer-Mannheim, Mannheim, FRG) is the only type of material currently available commercially. The only advantage of this. over in-house aqueous solutions. is the availability of a 'known' value. INTERPRETATION Plasma ammonia in venous blood of healthy adults and children (I month to 14years) is less than 40 tJ.mol/L31 and is not significantly affected by diet or fasting status. Several studies have shown healthy term infants to have higher levels. up to 100 umol/L, in the first 3 days of life and even higher levels (up to ISO umol/L) may occur in neonates if capillary blood is used." Healthy pre-term neonates may have levels up to twice those found in term infants and levels up to 200 umol/l, do not require further investigation providing the baby is well. 49 This neonatal hyperammonaemia found in pre-term infants may persist for up to 4-8 weeks. but has not been associated with any neurological deficit and there is no evidence to support the need for treatment.50 Ammonia concentrations in patients with the urea cycle defects presenting in the neonatal period are usually grossly increased and should not cause confusion.
Ammonia values obtained in the first few days of life. particularly from premature infants. should be interpreted with caution. Whenever possible arterial or venous blood specimens should be taken in preference to capillary blood.
